{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:10:53Z","timestamp":1783977053819,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejogrb.2026.115250","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:32:11Z","timestamp":1781566331000},"page":"115250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Possible correlations between infertility and adverse metabolic profile: a case-control study"],"prefix":"10.1016","volume":"324","author":[{"given":"Carmen Imma","family":"Aquino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Fortina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rigamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Minisini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Pirisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Remorgida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Bellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Surico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2026.115250_b0005","unstructured":"American Association for the Study of Liver Diseases (AASLD). New MASLD nomenclature (2023). Available at: https:\/\/www.aasld.org\/new-masld-nomenclature. Accessed on September 17, 2025."},{"key":"10.1016\/j.ejogrb.2026.115250_b0010","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0015","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0020","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0025","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years","volume":"59","author":"Wong","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.ejogrb.2026.115250_b0030","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejogrb.2026.115250_b0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12944-024-02092-2","article-title":"Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics","volume":"23","author":"Jiang","year":"2024","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ejogrb.2026.115250_b0040","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3390\/antiox13111386","article-title":"Gut microbiota and metabolic dysfunction-associated steatotic liver disease","volume":"13","author":"Scarpellini","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejogrb.2026.115250_b0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/nu17010143","article-title":"Dietary influences on gut microbiota and their role in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","author":"Hamamah","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.ejogrb.2026.115250_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1426551","article-title":"Diet and physical exercise as key players to tackle MASLD through improvement of insulin resistance and metabolic flexibility","volume":"11","author":"Mambrini","year":"2024","journal-title":"Front Nutr"},{"key":"10.1016\/j.ejogrb.2026.115250_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.ejogrb.2026.115250_b0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejogrb.2026.115250_b0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jceh.2019.07.008","article-title":"Extra-hepatic manifestations of nonalcoholic fatty liver disease: a review","volume":"10","author":"Tariq","year":"2020","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1017\/S0029665110000030","article-title":"Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome","volume":"69","author":"Moore","year":"2010","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.ejogrb.2026.115250_b0075","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2036.2011.04579.x","article-title":"Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease","volume":"33","author":"Baranova","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejogrb.2026.115250_b0080","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cgh.2006.10.010","article-title":"Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome","volume":"5","author":"Gambarin-Gelwan","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0085","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2007.04.012","article-title":"Nonalcoholic fatty liver disease in women with polycystic ovary syndrome","volume":"47","author":"Cerda","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0090","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/00365521.2010.539251","article-title":"Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS)","volume":"46","author":"Hossain","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186136","article-title":"Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS","volume":"12","author":"Petta","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejogrb.2026.115250_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ogrm.2018.12.001","article-title":"PCOS: diagnosis and management of related infertility","volume":"29","author":"Kriedt","year":"2019","journal-title":"Obstet Gynaecol Reprod Med"},{"key":"10.1016\/j.ejogrb.2026.115250_b0105","first-page":"274","article-title":"Nonalcoholic fatty liver disease, male sexual dysfunction, and infertility: common links","volume":"8","author":"Hawksworth","year":"2020","journal-title":"Common Problems Sex Med Rev"},{"issue":"S1","key":"10.1016\/j.ejogrb.2026.115250_b0110","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.5005\/jp-journals-10018-1370","article-title":"Gender differences in nonalcoholic fatty liver disease","volume":"12","author":"Al Mahtab","year":"2022","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0115","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/biomedicines13102542","article-title":"Does the type of cancer influence anti-M\u00fcllerian hormone levels in women of reproductive age? A cross-sectional study","volume":"13","author":"Caringella","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejogrb.2026.115250_b0120","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejogrb.2026.115250_b0125","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejogrb.2026.115250_b0130","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4093\/dmj.2018.0201","article-title":"Severity of nonalcoholic fatty liver disease in type 2 diabetes mellitus: relationship between nongenetic factors and PNPLA3\/HSD17B13 polymorphisms","volume":"43","author":"Bellan","year":"2019","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.ejogrb.2026.115250_b0135","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4216451","article-title":"Interplay of PNPLA3 and HSD17B13 variants in modulating the risk of hepatocellular carcinoma among hepatitis C patients","volume":"2020","author":"De Benedittis","year":"2020","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.ejogrb.2026.115250_b0140","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1478-3231.2011.02534.x","article-title":"PNPLA3 rs738409C\/G polymorphism in cirrhosis: Relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence","volume":"31","author":"Falleti","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.ejogrb.2026.115250_b0145","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1038\/s41598-017-04991-0","article-title":"MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals","volume":"7","author":"Donati","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejogrb.2026.115250_b0150","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1038\/s41598-019-39998-2","article-title":"Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease","volume":"9","author":"Pelusi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejogrb.2026.115250_b0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0160","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/liv.13972","article-title":"Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease","volume":"39","author":"Pelusi","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.ejogrb.2026.115250_b0165","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","author":"Tr\u00e9po","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0170","first-page":"857","article-title":"Decoding 17-beta-hydroxysteroid dehydrogenase 13: a multifaceted perspective on its role in hepatic steatosis and associated disorders","volume":"12","author":"Demirtas","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0175","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2026.115250_b0180","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.ejogrb.2026.115250_b0185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13073-020-00742-5","article-title":"Polygenic risk scores: from research tools to clinical instruments","volume":"12","author":"Lewis","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.ejogrb.2026.115250_b0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/hepr.14121","article-title":"Prognostic performance of a two-step method using the Fibro-Scope system for metabolic dysfunction-associated steatotic liver disease","volume":"55","author":"Seko","year":"2025","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ejogrb.2026.115250_b0195","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.cgh.2021.05.056","article-title":"A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores","volume":"20","author":"De Vincentis","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0200","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejogrb.2026.115250_b0205","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0210","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/joim.12719","article-title":"Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver","volume":"283","author":"Dongiovanni","year":"2018","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejogrb.2026.115250_b0215","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0220","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejogrb.2026.115250_b0225","series-title":"Current Medical Diagnosis & Treatment 2022","article-title":"Polycystic ovary syndrome","author":"Long","year":"2022"},{"key":"10.1016\/j.ejogrb.2026.115250_b0230","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s40618-017-0708-9","article-title":"Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis","volume":"40","author":"Rocha","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ejogrb.2026.115250_b0235","first-page":"56","article-title":"Complementary therapy in polycystic ovary syndrome","volume":"9","author":"Aquino","year":"2014","journal-title":"Transl Med UniSa"},{"key":"10.1016\/j.ejogrb.2026.115250_b0240","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/liv.14943","article-title":"Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease(NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"41","author":"Burra","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.ejogrb.2026.115250_b0245","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.molmed.2024.05.013","article-title":"Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Cherubini","year":"2024","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ejogrb.2026.115250_b0250","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.bpobgyn.2014.11.001","article-title":"Polycystic ovaries and obesity","volume":"29","author":"Messinis","year":"2015","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0255","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1067\/mob.2000.107627","article-title":"Induction of ovulation in infertile women with hyperandrogenism and insulin resistance","volume":"183","author":"Barbieri","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0260","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1194\/jlr.P067454","article-title":"Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study1","volume":"58","author":"Krawczyk","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejogrb.2026.115250_b0265","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jcmgh.2021.11.007","article-title":"TM6SF2\/PNPLA3\/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models","volume":"13","author":"Longo","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0270","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16103","article-title":"Integrating PNPLA3 into clinical risk prediction","volume":"45","author":"Chen","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.ejogrb.2026.115250_b0275","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ueg2.12513","article-title":"Predictors of controlled attenuation parameter in metabolic dysfunction","volume":"12","author":"Bianco","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.ejogrb.2026.115250_b0280","first-page":"579","article-title":"Accuracy of controlled attenuation parameter for liver steatosis in patients at risk for metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging: a systematic review and meta-analysis","volume":"37","author":"Malandris","year":"2024","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.ejogrb.2026.115250_b0285","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s10620-024-08799-7","article-title":"Accuracy of controlled attenuation parameter for liver steatosis in high-risk patients for MASLD using MRI-proton density fat fraction as reference standard","volume":"70","author":"Malandris","year":"2025","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ejogrb.2026.115250_b0290","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16088","article-title":"Sex-specific effects of PNPLA3 I148M","volume":"45","author":"Cherubini","year":"2025","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.ejogrb.2026.115250_b0295","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/biomedicines13102542","article-title":"Does the type of cancer influence anti-M\u00fcllerian hormone levels in women of reproductive age? A cross-sectional study","volume":"13","author":"Caringella","year":"2025","journal-title":"Biomedicines"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211526003180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211526003180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:28:06Z","timestamp":1783974486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211526003180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":59,"alternative-id":["S0301211526003180"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2026.115250","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible correlations between infertility and adverse metabolic profile: a case-control study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2026.115250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115250"}}